ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.07
-0.32 (-1.17%)
Feb 21, 2025, 4:00 PM EST - Market closed
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 38, with a low estimate of 36 and a high estimate of 39. The average target predicts an increase of 40.38% from the current stock price of 27.07.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
The average analyst rating for ArriVent BioPharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $39 | Strong Buy | Maintains | $36 → $39 | +44.07% | Jan 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +32.99% | Nov 15, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $30 → $36 | Strong Buy | Maintains | $30 → $36 | +32.99% | Sep 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $35 → $39 | Buy | Reiterates | $35 → $39 | +44.07% | Sep 10, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $38 | Strong Buy | Maintains | $28 → $38 | +40.38% | Sep 10, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.75
from -32.38
EPS Next Year
-3.31
from -2.75
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 10.2M | |||
| Avg | n/a | n/a | 4.9M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.66 | -2.37 | -2.16 |
| Avg | -2.75 | -3.31 | -3.77 |
| Low | -2.84 | -3.72 | -4.34 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.